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Eurycomanone is a compound found in Eurycoma longifolia Jack and has 
been reported that it had a cytotoxic effect against various cancer cell lines. 
The aim of this study was to isolate eurycomanone from the roots of E. 
longifolia, investigate the cytotoxicity against human hepatoma cell line, 
HepG2, and determine the mode of action. In vivo study using nude mice as 
an animal model was also carried out to further confirm the ability of 
eurycomanone in liver cancer suppression. Eurycomanone was extracted 
from the roots of E. longifolia. The methanol extract was partitioned with 
diethylether, saturated with water. The aqueous soluble portion was further 
partitioned with butanol (BuOH) and water. The BuOH-soluble portion was 
subjected to silica gel column chromatography, TLC and finally HPLC to 
afford eurycomanone.  
 
The anti-proliferation assay was carried out using the MTT Cell Proliferation 
Assay. The cells were treated with crude extract of E. longifolia (CE) and 
eurycomanone at increasing concentrations for 72 hours. The findings 
showed that CE inhibited cell proliferation towards human malignant 
melanoma cell (HM3KO), human cervical cancer cell (Hela), human liver 
cancer cell (HepG2) and human ovarian carcinoma cell (CaOV3) with an IC50 
of 60±0.25 µg/ml, 60±0.25 µg/ml, 45±0.15 µg/ml and 79±0.16 µg/ml 
respectively. The extracts did not inhibit the cell proliferation for both normal 
cell lines used, human normal skin cell (CCD11114sk), and human normal 
liver cells, Chang’s liver. The activity of eurycomanone towards HepG2 gave 
an IC50 of 3.8±0.12 µg/ml and significantly increased apoptosis in HepG2 
cells. Eurycomanone also showed less toxicity towards both normal liver 
cells, Chang’s liver (17±0.15 μg/ml) and WLR-68 (20±0.22 μg/ml) as 
compared to tamoxifen (1.4±0.31 μg/ml) and vinblastine sulfate (4.2±0.37 
μg/ml).  
 
In vivo study confirmed the effect of eurycomanone in the inhibition of tumor 
growth. Nude mice were inoculated with HepG2 cells, subcutaneously in the 
right flank. When the tumor volume reached 100 mm3, eurycomanone (6 
mg/kg and 17 mg/kg) was applied intraperitoneally once a day, for 30 days. 
CE was also administered to the mice bearing tumor to compare the 
effectiveness between both of them.  Data showed that tumor size in mice 
treated with eurycomanone was significantly reduced at concentration of 17 
mg/kg compared to control and CE. Relative tumor growth ratio (TC) was 
calculated with percentage value of 39.9% and relative tumor volume (RTV) 
of 1.5±0.09 was recorded. Growth reduction was associated with significantly 
reduced mitotic index. Hoechst 33258 staining was carried out in vitro, to 
prove the presence of apoptosis in HepG2 cells treated with eurycomanone 
(5 μg/ml). The characteristics of apoptosis including chromatin condensation, 
DNA fragmentation and apoptotic bodies were found following 
eurycomanone treatment. Further investigation on the cell cycle progression 
in HepG2 cells under eurycomanone treatment using a flow cytometry 
approach with PI staining was done. The cell cycle distribution was examined 
at various times and indicated doses. Vinblastine sulfate and genistein were 
used as a positive control. Eurycomanone appeared to affect processes that 
could inhibit the cell proliferation by inducing G2/M arrest in a time-dependent 
manner in HepG2 cells, with 39.9% of cells accumulated in G2/M phase. 
Flow cytometry with annexin-V/propidium iodide double staining was carried 
out to further confirm that eurycomanone induced apoptosis in HepG2 cells. 
Eurycomanone was shown to induce apoptosis in HepG2 cells in a time-
dependent manner. After 72 hrs of exposure, only 5.6% cells were alive 
indicating that almost all of the cells underwent apoptosis. In the quadrant of 
annexin V+/PI-, 74.1% of the cells were detected. Increased cell population 
was observed at late apoptotic quadrant with a percentage of 15.3%. The 
protein expression of Bcl-2, Bax, p53 and cytochrome C were studied via 
flow cytometry in order to find the mechanism of action of eurycomanone. 
This study found that the apoptotic process triggered by eurycomanone 
involves the up-regulation of p53 tumor suppressor protein. The increased of 
p53 was followed by an increase of pro-apoptotic Bax and decrease of anti-
apoptotic Bcl-2. Active Bax and inactive Bcl-2 induced the level of 
cytochrome C which leads to apoptosis.  
 
In conclusion, this present study indicated that eurycomanone has cytotoxic 
effect towards HepG2 cells. In vivo study suggested that eurycomanone has 
a high potential in inhibiting solid tumor growth in mice. These findings also 
concluded that the anticancer effect of eurycomanone against HepG2 cells 
was via inducing apoptosis through the up-regulation of p53 and Bax, and 
down-regulation of Bcl-2 which increased the levels of cytochrome C. 
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Eurikomanon merupakan sebatian yang terkandung di dalam E. longifolia 
Jack di mana kajian terdahulu menunjukkan bahawa ia mempunyai kesan 
ketoksikan terhadap beberapa jenis titisan sel kanser. Kajian ini bertujuan 
untuk memencilkan eurikomanon daripada E. longifolia, mengkaji kesan 
ketoksikan terhadap sel kanser hepar manusia, HepG2 dan menentukan 
mekanisme tindakannya. Kajian secara in vivo menggunakan tikus ‘nude’ 
sebagai model haiwan juga dilakukan untuk mengesahkan lagi keupayaan 
eurikomanon dalam merencat pertumbuhan sel kanser hepar. Eurikomanon 
diekstrak daripada akar E. Longifolia. Ekstrak metanol dipartisikan dengan 
dietileter dan air. Fraksi larut air kemudian dipartisikan dengan butanol dan 
air. Fraksi larut butanol seterusnya dilakukan kromatografi silika gel, TLC dan 
HPLC bagi mendapatkan sebatian aktif eurikomanon.  
Asai antiproliferatif dijalankan menggunakan kaedah MTT. Sel didedahkan 
dengan ekstrak kasar E. Longifolia (EK) dan eurikomanon pada kepekatan 
yang semakin meningkat selama 72 jam. Hasil kajian menunjukkan ekstrak 
kasar E. longifolia merencat proliferasi sel kanser kulit manusia (HM3KO), sel 
kanser serviks manusia (Hela), sel kanser hati manusia (HepG2) dan sel 
kanser ovari manusia (CaOV3) dengan IC50 masing-masing 60±0.25 µg/ml, 
60±0.25 µg/ml, 45±0.15 µg/ml dan 79±0.16 µg/ml. Ekstrak kasar tidak 
menunjukkan kesan perencatan pada kedua-dua sel normal yang digunakan 
iaitu sel normal kulit manusia (CCD11114sk) dan sel normal hepar manusia, 
Chang’s liver. Eurikomanon juga memberikan aktiviti antikanser yang tinggi 
terhadap sel HepG2. Eurikomanon secara signifikan merencat pertumbuhan 
sel HepG2 dengan IC50 3.8±0.12 µg/ml dan mengaruh apoptosis. 
Eurikomanon juga menunjukkan kesan ketoksikan yang lebih rendah terhdap 
kedua-dua sel normal hepar manusia, Chang’s liver (17±0.15 µg/ml) dan 
WLR-68 (20±0.22 µg/ml) jika dibandingkan dengan tamoxifen (1.4±0.31 
µg/ml) dan vinblastin sulfat (4.2±0.15 µg/ml).  
 
Kajian in vivo mengesahkan kesan eurikomanon dalam merencat 
pertumbuhan kanser. Tikus ‘nude’ diinokulat dengan sel HepG2 secara 
suntikan bawah kulit pada bahagian rusuk kanan. Apabila isipadu tumor 
mencapai 100 mm3, eurikomanon (6 mg/kg dan 17 mg/kg) diberikan secara 
suntikan bawah perut, sekali sehari selama 30 hari. EK juga diberikan 
kepada tikus yang telah ditumbuhi tumor untuk membandingkan 
keberkesanan antara keduanya. Data menunjukkan saiz tumor yang dirawat 
eurikomanon menurun secara signifikan pada kepekatan 17 mg/kg 
dibandingkan dengan kawalan dan EK. 39.9% nilai TC (nisbah pertumbuhan 
relatif tumor) dicatat dengan RTV (isipadu relatif tumor) 1.5±0.09. Penurunan 
kadar pertumbuhan selari dengan penurunan indeks mitotik.  
 
Pewarnaan Hoechst 33258 dilakukan untuk mengesahkan bahawa apoptosis 
berlaku dalam sel yang dirawat eurikomanon. Ciri-ciri apoptosis termasuk 
kondensasi kromatin, fragmentasi DNA dan kehadiran badan apoptotik 
dikesan berikutan rawatan eurikomanon. Kajian selanjutnya dijalankan untuk 
melihat kesan eurikomanon dalam merencat kitar sel menggunakan 
sitometer aliran. Vinblastin sulfat dan genistein diguna sebagai kawalan 
positif. Eurikomanon didapati memberi kesan terhadap sel HepG2 dengan 
mengaruh penahanan sel pada fasa G2/M bergantung kepada masa 
pendedahan dengan 39.9% sel dicatatkan. Sitometer aliran menggunakan 
annexin-V/PI dilakukan untuk mengesahkan lagi bahawa eurikomanon 
mengaruh apoptosis pada sel HepG2. Selepas 72 jam diberikan 
eurikomanon, hanya 5.6% sel yang masih hidup, menunjukkan sebahagian 
besarnya telah mengalami apoptosis. 7.1%  daripada sel dikesan dalam 
kuadrant V+/PI-, tetapi peningkatan populasi sel dicatat pada kuadrant fasa 
akhir apoptosis dengan nilai 15.3%. Kajian terhadap pengekspresan protein 
Bcl-2, Bax, p53 dan sitokrom C dilakukan untuk mengenalpasti mekanisme 
tindakan eurikomanon. Antibodi spesifik terhadap protein-protein tersebut 
digunakan dalam analisis menggunakan sitometer aliran. Hasil mendapati 
proses apoptosis yang dicetuskan oleh eurikomanon melibatkan peningkatan 
protein p53. Peningkatan p53 diikuti oleh peningkatan Bax dan penurunan 
Bcl-2 yang seterusnya membawa kepada peningkatan sitokrom C yang akan  
mengaktifkan proses apoptosis.  
 
Kesimpulannya, hasil kajian mencadangkan eurikomanon mempunyai 
potensi yang tinggi dalam merencat pertumbuhan tumor in vivo. Berdasarkan 
kajian ini juga, dapat disimpulkan bahawa eurikomanon adalah toksik 
terhadap sel HepG2 dengan mengaruh apoptosis melalui peningkatan p53 
dan Bax, dan menurunkan aras Bcl-2 yang akan mengaruh peningkatkan 
aras sitokrom C. 
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genistein (5 µg/ml) under four situations in quadrant  
analysis; living cells (A3), apoptotic cells (A4), late apoptotic  
or dead cells (A2) and necrotic or dead cells (A1). Exposed  
for 24 h, 48 h and 72 h. 
 
1755.25 The histogram show the percentage of viable, apoptotic  
and necrotic of HepG2 cells treated with genistein (5 µg/ml),  
analyzed by flow cytometry. 
 
 
5.26 Scatter plots of Ann/PI-stained untreated WLR-68 cells  176 
under four situations in quadrant analysis; living cells (A3),  
apoptotic cells (A4), late apoptotic or dead cells (A2) and  
necrotic or dead cells (A1). Exposed for 24 h, 48 h and 72 h. 
 
177 5.27 The histogram show the percentage of viable, apoptotic  
and necrotic of untreated WLR-68 cells (positive control),  
analyzed by flow cytometry. 
 
178 5.28 Scatter plots of Ann/PI-stained WLR-68 cells  
treated with eurycomanone (5 µg/ml) under four situations  
in quadrant analysis; living cells (A3), apoptotic cells  
(A4), late apoptotic or dead cells (A2) and necrotic or  
dead cells (A1). Exposed for 24 h, 48 h and 72 h.   
      
180 5.29 The histogram show the percentage of viable, apoptotic  
and necrotic of WLR-68 cells treated with eurycomanone  
(5 µg/ml), analyzed by flow cytometry. 
 
5.30 Scatter plots of Ann/PI-stained WLR-68 cells treated with  181 
vinblastine sulfate (2.5 µg/ml) under four situations in  
quadrant analysis; living cells (A3), apoptotic cells (A4),  
late apoptotic or dead cells (A2) and necrotic or dead 
cells (A1). Exposed for 24 h, 48 h and 72 h. 
 
5.31 The histogram show the percentage of viable, apoptotic  182 and necrotic of WLR-68 cells treated with vinblastine  
sulfate (2.5 µg/ml), analyzed by flow cytometry. 
 
186 5.32 The profile of Bax expression proteins for untreated  
HepG2 cells, HepG2 cells treated with eurycomanone  
and vinblastine sulfate at 24 h, 48 h and 72 h. 
 
187 5.33 The profile of Bcl-2 expression protein for untreated  
HepG2 cells, HepG2 cells treated with eurycomanone  
and vinblastine sulfate at 24 h, 48 h and 72 h. 
 
190 5.34 The profile of p53 expression proteins for untreated  
HepG2 cells, HepG2 cells treated with eurycomanone  
and vinblastine sulfate at 24 h, 48 h and 72 h. 
 
191 5.35 The profile of cytochrome C expression proteins for  
untreated HepG2 cells, HepG2 cells treated with  
eurycomanone and vinblastine sulfate at 24 h, 48 h and  
72 h. 
 
192 5.36 The histogram of the expression levels of Bcl-2, Bax,  
p53 and Cytochrome C in untreated HepG2 cells, HepG2  
cells treated with eurycomanone and HepG2 cells  
treated with vinblastine sulfate.  
 
6.1 The propose mechanism of action for eurycomanone- 204 
mediated apoptosis in human liver cancer cells, HepG2. 
 
 
 
 
  
 
 
 
 
 
LIST OF ABBREVIATIONS 
 
γ-GT   gamma-glutamyl transpeptidase 
ACN   Acetonitrile 
ACUC   Animal Care Unit Commitee 
AFB1   Aflatoxin B1 
AFP   Alfa-fetoprotein 
AIDS   Acquired immune deficiency syndrome 
AIF   Apoptosis-inducing factor 
Apaf-1  Apoptotic protease activating factor-1 
ASEAN   Association of Southeast Asian Nations 
ATCC   American Type Culture Collection 
BH   Bcl-2 homology domains 
BuOH   Butanol 
BW   Body weight 
CaOV3  Human ovarian carcinoma cell 
CCD11114sk Human normal skin cell 
CDK   Cyclin-dependent kinases 
CE   Crude extract of E. longifolia 
CKI   Cyclin-dependent kinase inhibitor 
DCP   des-γ-carboxy prothrombin 
DMEM  Dulbecco’s Modified Eagle’s Medium 
DMSO  Dimethylsulfoxide 
DNA   Deoxyribonucleic acid 
EDTA   Ethyline diamine tetra acetic acid 
EGCG  Epigallocathecin gallate 
ELISA   Enzyme-Linked Immunosorbent Assay 
